Equillium, INC Form 4 insider transactions

Daniel Bradbury, Executive Chairman of Equillium, Inc., reports acquiring and disposing of employee stock options following the lapse of a holding period related to a previous repricing.

Bruce D. Steel, President and CEO of Equillium, Inc., reports the acquisition and disposal of employee stock options following the lapse of a holding period related to option repricing.

Director Mark Pruzanski reports the acquisition and disposal of Equillium, Inc. stock options following the lapse of a holding period related to option repricing.

Director Martha Demski reports transactions related to stock options of Equillium, Inc. following the lapse of a holding period after repricing.

Director Bala Manian reports transactions related to stock options in Equillium, Inc. following the lapse of a holding period related to option repricing.

Equillium's Chief Financial Officer, Jason Keyes, reports the acquisition and disposal of employee stock options following the lapse of a holding period related to option repricing.

Principal Accounting Officer Tom Penny reports the repricing of certain stock options and the grant of new options following the lapse of a holding period.

Director Barbara Troupin reports transactions related to the repricing of stock options, resulting in adjustments to derivative security holdings.

Equillium's Chief Financial Officer, Jason A. Keyes, sold 10,000 shares of common stock at an average price of $0.65, as part of a pre-arranged 10b5-1 trading plan.

Equillium Inc.'s Principal Accounting Officer, Tom Penny, was granted 125,000 stock options on January 2, 2025.

Equillium's President and CEO, Bruce D. Steel, has acquired 410,000 employee stock options at an exercise price of $0.77.

Daniel Bradbury, Executive Chairman of Equillium, Inc., acquired 50,000 employee stock options on January 2, 2025, at an exercise price of $0.77 per share.

Equillium's Chief Financial Officer, Jason Keyes, acquired 15,000 shares and 175,000 stock options, according to a recent SEC filing.

Christine Zedelmayer, Senior Vice President and COO of Equillium Inc., acquired 175,000 employee stock options on January 2, 2025.

Stephen Connelly, Chief Scientific Officer of Equillium, Inc., acquired 175,000 employee stock options on January 2, 2025.

Director Peter Colabuono of Equillium, Inc. was granted 40,000 stock options on December 11, 2024.

Equillium's Chief Financial Officer, Jason Keyes, sold 10,000 shares of common stock at a weighted average price of $0.70, as part of a pre-arranged 10b5-1 trading plan.

Christine Zedelmayer, Sr. VP and COO of Equillium, Inc., sold 15,000 shares of common stock at $1.25 per share on October 28, 2024, according to a Form 4 filing.

Tom Penny, Principal Accounting Officer of Equillium, Inc., sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Equillium's Chief Financial Officer, Jason Keyes, sold 10,000 shares of common stock at an average price of $0.81, according to a Form 4 filing with the SEC.

Principal Accounting Officer Tom Penny reports selling 38,806 shares of Equillium, Inc. common stock at an average price of $0.85 per share.

Equillium's Chief Financial Officer, Jason Keyes, sold 10,000 shares of common stock on July 16, 2024, at an average price of $0.87, according to a Form 4 filing with the SEC.

Director Martha J. Demski reports the acquisition of stock options in Equillium, Inc.

Director Mark Pruzanski acquired 20,000 stock options in Equillium, Inc. on May 22, 2024.

Director Bala S. Manian acquired 20,000 stock options in Equillium, Inc. on May 22, 2024.

Charles Douglas McDermott, a director of Equillium, Inc., acquired stock options for 20,000 shares on May 22, 2024.

Director Yu (Katherine) Xu of Equillium, Inc. acquired 20,000 stock options on May 22, 2024, according to a recent SEC Form 4 filing.

Director Barbara Troupin acquired 20,000 stock options in Equillium, Inc. on May 22, 2024.